• HRT Game-Changer for Women's Health with Sara Hover
    Feb 13 2026
    FDA Removes Black Box Warning on Estrogen: HRT Game-Changer for Women's Health After 23 years, the FDA removed the black box warning on estrogen products—a landmark decision transforming hormone replacement therapy (HRT) for women. In this episode of the Mortar and Pestle podcast, hosts Mike De Lisio and Sebastian Dennison discuss this breakthrough with Sara Hover, Senior Director of Clinical Services at PCCA. What You'll Learn:
    • Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concerns
    • The timing hypothesis: why age matters when starting hormone replacement therapy
    • Synthetic vs. bioidentical hormones and their clinical differences
    • Oral estrogen delivery systems and safety implications
    • Shared decision-making between patients, prescribers, and pharmacists
    • Why compounded HRT solutions matter for patients who don't fit commercial products
    • Hormone testing modalities and why multiple testing methods are essential
    • Vaginal estrogen's role in preventing UTIs and hip fractures
    • How pharmacists can educate providers and patients on HRT safety
    Topics Covered: Black box warning removal, hormone replacement therapy, bioidentical hormones, menopause management, compounding pharmacy, women's health, estrogen, patient monitoring, HRT dosing strategies Perfect for: Compounding pharmacists, healthcare providers, and anyone seeking evidence-based information on hormone replacement therapy. Links: The FDA Removes the Black Box Warning on Estrogen: What Pharmacists Need to Know (2025 Update) Why VersaBase Cream Is Your Best Choice for Women's HRT The Vaginal Microbiome, Menopause & HRT A Personalized Approach to HRT for Perimenopausal Women Backed by Science: Anhydrous VersaBase® HRT Optimizing the Patient Experience with the Right HRT Base: Insights from the Webinar
    Show more Show less
    28 mins
  • Methylene Blue Topical Formulations and Advanced Dermatology Compounding Strategies with Nat Jones
    Jan 29 2026
    In this episode, discover innovative dermatology compounding formulations featuring methylene blue for anti-aging skincare. Clinical pharmacist Nat Jones discusses PCCA's USP-grade methylene and the need for quality. Methylene blue may play a role in collagen stimulation, hyaluronic acid production, and UV protection. Also, learn about bio-peptide cream bases, research on carbamazepine and plaque psoriasis as well as research on losartan and hypertrophic scars. Explore evidence-based topical treatments that may be appropriate for patients in compounding pharmacies. Perfect for pharmacists seeking advanced dermatological formulation strategies and cosmeceutical applications.

    Learn more by visiting our blog: Methylene Blue: Something Old and Something Blue

    Working with Methylene Blue: Best Practices for Compounding and Cleanup

    Methylene Blue: From Textile Dye to Potential Clinical Wonder
    Show more Show less
    26 mins
  • Industry Leader: APC Blue Print with Tenille Davis and Erin Micheal
    Nov 3 2025

    In this episode of a Mortar and Pestle, Tenille Davis, Chief Advocacy Officer for the Alliance for Pharmacy Compounding, joins host Mike De Lisio and guest co-host Erin Michael, Director of Member Engagement, to discuss the APC Blue Print, a blueprint for eliminating redundant, unauthorized, or ineffective regulation that impedes patient access to compounded drugs.

    Show more Show less
    23 mins
  • Introducing UniFlow with Courtaney Davis and Daniel Banov
    Oct 9 2025

    In this episode of a Mortar and Pestle, Vice President of Research and Development Daniel Banov and Senior Formulation Specialist Courtaney Davis join host Vice President of North American Sales Mike De Lisio and co-host Clinical Compounding Pharmacist, RPh, FAARM (Candidate) Sebastian Denison, to discuss PCCA’s newest base innovation, UniFlow ­— a game changer in T3 and T4 compounding.

    Show more Show less
    40 mins
  • Leucovorin and other Supplements for Autism with Tricia Heitman
    Sep 18 2025

    In this episode of a Mortar and Pestle, Tricia Heitman, PharmD, joins host Mike De Lisio, Vice President of North American Sales, and co-host Sebastian Denison, Clinical Compounding Pharmacist, RPh, FAARM (Candidate) to discuss leucovorin and other supplements for autism.

    Show more Show less
    23 mins
  • Navigating Testosterone, Stress & Wellness with Ranel Larsen
    Sep 4 2025

    In this episode of The Mortar & Pestle Podcast, pharmacist and hormone therapy expert Ranel Larsen joins Mike de Lisio, Vice President of North American Sales, and Sebastian Denison, Clinical Compounding Pharmacist, RPh, FAARM (Candidate), to dig into men’s health. From hormone replacement therapy and lab testing to lifestyle factors like stress, sleep, and nutrition, Ranel breaks down how pharmacists can better support male patients while debunking common myths around testosterone.

    Show more Show less
    46 mins
  • Live from the 2025 PCCA Technician Summit with Tiffany Kofroth, CSPT, CPhT-Adv & Mindy Stephens
    Aug 21 2025

    In this special live episode of Tech Talk, a Mortar & Pestle production, Erin Michael, Director of Member Engagement, is joined by Tiffany Kofroth, CSPT, CPhT-Adv, Advanced Pharmacy Technician in Continuing Pharmacy Education at the University of Texas at MD Anderson Cancer Center from and Mindy Stephens, as they discuss their compounding journeys.

    Show more Show less
    46 mins
  • SubMagna® HMW with Richie Ray
    Aug 7 2025

    In this episode of The Mortar & Pestle: A PCCA Podcast, host Mike de Lisio is joined by PCCA’s VP of R&D, Daniel Banov, and returning guest Richie Ray, owner of Richie Specialty Pharmacy, to explore the innovation and impact of SubMagna—a proprietary sublingual base developed by PCCA. They discuss the technical challenges and scientific breakthroughs involved in formulating SubMagna to effectively deliver high molecular weight peptides like semaglutide via the sublingual route. Daniel details the base’s development process, including surfactant balancing, solubility enhancement, and permeability optimization, while Richie shares clinical insights, patient responses, and the broader market implications. Together, they highlight SubMagna’s potential as a game-changing delivery system for peptides and other challenging APIs, especially in an era of rising demand for non-injectable therapies.

    Show more Show less
    45 mins